




FOR EARLY- AND LATE-STAGE PROSTATE CANCER

Navigate your patient's journey
with Oncotype DX[®] tests

*oncotype*DX[®]
Genomic Prostate Score

*oncotype*DX[®]
AR-V7 Nucleus Detect
powered by Epic Sciences



**FOR YOUR
EARLY-STAGE
PATIENTS**


oncotypeDX[®]
Genomic Prostate Score

**FOR YOUR
LATE-STAGE
PATIENTS**

oncotypeDX[®]
AR-V7 Nucleus Detect
powered by Epic Sciences

Refines clinical risk assessment in Gleason Score 3+3 and 3+4 patients for more precise treatment decisions

Guides mCRPC treatment decisions for improved patient outcomes when AR-targeted therapy fails



[†]Androgen receptor (AR)-targeted therapies include Erleada™ (apalutamide), Zytiga® (abiraterone), and Xtandi® (enzalutamide).

AR-V7 Nucleus Detect, Genomic Prostate Score, Oncotype DX AR-V7 Nucleus Detect, and Oncotype DX Genomic Prostate Score are trademarks of Genomic Health, Inc. All other trademarks are the properties of their respective owners.
© 2019 Genomic Health, Inc. All rights reserved. GHI60039_0419

Partner with Genomic Health on management and treatment decisions for your prostate cancer patients

COVERED BY **MEDICARE**

FOR YOUR
EARLY-STAGE
PATIENTS

oncotype **DX**[®]
Genomic Prostate Score

Guide treatment decisions for your Gleason Score 3+3 and 3+4 patients.

FOR YOUR
LATE-STAGE
PATIENTS

oncotype **DX**[®]
AR-V7 Nucleus Detect
powered by Epic Sciences

Determine the next treatment step for your mCRPC patients who have failed an AR-targeted therapy.

LEARN MORE about the **GPS**[™] and **AR-V7 Nucleus Detect**[®] assays

Contact your local Genomic Health representative or Customer Service at 866 ONCOTYPE (866-662-6897).

Genomic Health also offers the Genomic Access Program (GAP), a patient assistance program. To learn more about GAP, contact 888 ONCOTYPE (888-662-6897) or customerservice@genomichealth.com.

Over 1 million breast, colon, and prostate cancer patients have used an Oncotype DX assay to help guide their treatment decisions

Genomic Health, GPS, Oncotype DX, Oncotype DX AR-V7 Nucleus Detect, Oncotype DX Genomic Prostate Score, and Oncotype IQ are trademarks of Genomic Health, Inc. All other trademarks are the properties of their respective owners.

© 2019 Genomic Health, Inc. All rights reserved. GHI60039_0419

oncotype **IQ**[®]
Genomic Intelligence Platform

Genomic Health[™]
LIFE. CHANGING.